Clinical & Diagnostic

FloBio's Bleeding Risk Diagnostic Test Earns FDA's Breakthrough Device Designation

Rapid Detection of Modern Blood Thinners Could Reduce Preventable Complications in US Hospitals...

BGI Genomics Combats Hepatitis in Ethiopia

Healthcare localization and standardization support the Belt and Road Initiative...

Voom Medical Devices Introduces Next Generation, Functionally Distinctive Patented Screw

Voom™ Medical Devices launches the distinctive patented Revcon™ Anchor v2.0 screw, the only neutral non-compressive dual-zone pitched single screw solution for minimally invasive bunion surgery, exclusively used with the Bunionplasty® procedure....

GE Healthcare Gets FDA Clearance for Allia IGS Pulse: Next-Gen Cardiac Imaging System

GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size....

IIT-D ( India ) designs scalable wearable pressure sensor to analyse gait patterns and postural deformities

Sensor can potentially provide an easy, low-cost alternative to expensive footwear modifications...

Boston Scientific Gets FDA Nod for Spinal Cord Stimulation in Diabetic Neuropathy

Nearly 50% of American adults living with diabetes will be affected by diabetic neuropathy complications in their lifetime...

Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease – amyloid plaques, tau tangles and neurodegeneration (ATN) – which can help accelerate the path to diagnosis and intervention.i The test is available through physicians for use with patients ...

Sigrid Therapeutics Announces First Patient Treated with SiPore21® Medical Device for Sustained Diabetes and Obesity Control

Sigrid Therapeutics announces the commencement of the SHINE clinical trial for SiPore21® – an innovative medical device designed for sustained diabetes and weight control. Based on Mesoporous Silica particles (MSPs), SiPore21® represents a groundbreaking approach to managing these pressing health concerns. Administered orally in gel form, MSPs act as "molecular sieves," physically preventing digestive enzymes from interacting with food, thereby reducing the breakdown of carbohydrates and fats....

DELFI Diagnostics Introduces FirstLook Lung: A Breakthrough in Blood-Based Lung Cancer Screening

FirstLook Lung uses a breakthrough technology of whole-genome machine learning to analyze fragments of cell-free DNA that are markers of cancer in the blood...